8-K: Madrigal Pharmaceuticals Announces Preliminary Q4 and Full-Year 2024 Net Sales, Exceeding Expectations with Rezdiffra

Madrigal Pharmaceuticals reports strong preliminary net sales for Q4 and full-year 2024 driven by Rezdiffra, with significant patient uptake and a solid cash position.

Summary

• Madrigal Pharmaceuticals announced preliminary net sales for the fourth quarter of 2024 in the range of $100 million to $103 million.
• Full-year 2024 net sales are estimated to be between $177 million and $180 million.
• The company's preliminary cash, cash equivalents, restricted cash, and marketable securities totaled approximately $931 million as of December 31, 2024.
• More than 11,800 patients were on Rezdiffra as of year-end 2024.
• Madrigal anticipates an EMA decision for Rezdiffra in mid-2025, with a European launch expected to commence in Germany in the second half of 2025, subject to EMA approval.
• The MAESTRO-NASH OUTCOMES study, evaluating Rezdiffra in patients with compensated MASH cirrhosis, has completed enrollment.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong preliminary sales figures, a solid cash position, and progress in clinical trials and regulatory approvals. The company's strategic focus on expanding market reach and addressing a significant unmet medical need contributes to the positive sentiment.

Positives

• Rezdiffra received U.S. FDA approval, becoming the first and only approved MASH therapy.
• The company has built an expert team for the launch of Rezdiffra.
• The MAESTRO-NASH trial results were published in The New England Journal of Medicine and recognized as a notable scientific research article.
• EMA validated the Marketing Authorization Application (MAA) for Rezdiffra.
• The company is preparing for European expansion in the second half of 2025.

Risks

• The reported financial results are preliminary and unaudited, subject to adjustment upon completion of financial closing procedures.
• Obtaining and maintaining regulatory approvals, including potential delays or rejections, pose a risk.
• The commercial launch of a new product, especially for a company without extensive commercial experience, presents challenges.
• The company has a history of operating losses and may not achieve or maintain profitability.
• Clinical studies are subject to risks, including enrollment challenges, adverse safety events, and uncertainties in achieving objectives.
• Market demand for and acceptance of Rezdiffra are uncertain.
• The company may face difficulties in raising sufficient capital to fund ongoing operations or obtaining financing on acceptable terms.
• Cyber-attacks pose a risk that needs to be prevented and mitigated.

Future Outlook

Madrigal is pursuing additional growth opportunities, including preparing for European expansion in the second half of 2025 and awaiting results from the MAESTRO-NASH OUTCOMES trial, which could further expand Rezdiffra's market.

Management Comments

• Bill Sibold, Chief Executive Officer of Madrigal, stated, '2024 was a transformational year for Madrigal and the MASH field.'
• Sibold continued, 'As we build momentum in the U.S., we are pursuing additional growth opportunities, including preparing for European expansion in the second half of 2025.'

Industry Context

Madrigal's announcement highlights the growing importance of treatments for MASH, which is expected to become the leading cause of liver transplants in the U.S. The company's focus on reaching patients with moderate to advanced fibrosis aligns with the increasing awareness and prevalence of the disease.

Comparison to Industry Standards

• Given that Rezdiffra is the first approved treatment for MASH, there are no direct competitors with approved therapies for comparison.
• Other companies like Intercept Pharmaceuticals (prior to their Ocaliva NASH program termination) and Viking Therapeutics are developing treatments for MASH, but they are in earlier stages of clinical development.
• Madrigal's $177-180 million in sales for the year is a strong start for a novel therapy in this space, and will be closely watched by the market.

Stakeholder Impact

• Shareholders can expect potential value appreciation due to strong sales and future growth prospects.
• Employees may benefit from job security and growth opportunities within the company.
• Patients with MASH have access to a new treatment option.
• Suppliers and partners may experience increased business opportunities.
• Creditors can be reassured by the company's strong financial position.

Next Steps

• Madrigal will announce complete financial results in February 2025.
• The company awaits an EMA decision for Rezdiffra in mid-2025.
• Madrigal plans to commence the European launch of Rezdiffra in the second half of 2025, starting with Germany, subject to EMA approval.
• The company will continue to monitor and analyze data from the MAESTRO-NASH OUTCOMES study.

Key Dates